Trial Profile
A Multinational, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 20 Oct 2023
Price :
$35
*
At a glance
- Drugs Semuloparin (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics; Registrational; Therapeutic Use
- Acronyms SAVE-ONCO
- Sponsors Sanofi
- 23 Jun 2012 EudraCT reports Actual Initiation Date is 29 Jul 2008.
- 19 Jun 2012 Results published in Annals of Internal Medicine.
- 13 Dec 2011 Results presented at the 53rd Annual Meeting and Exposition of the American Society of Hematology.